stoxline Quote Chart Rank Option Currency Glossary
  
Nanobiotix S.A. (NBTX)
5.35  -0.15 (-2.73%)    06-13 16:00
Open: 5.32
High: 5.41
Volume: 2,537
  
Pre. Close: 5.5
Low: 5.32
Market Cap: 252(M)
Technical analysis
2024-06-13 4:45:05 PM
Short term     
Mid term     
Targets 6-month :  7.79 1-year :  8.77
Resists First :  6.67 Second :  7.51
Pivot price 6.29
Supports First :  5.32 Second :  4.42
MAs MA(5) :  5.55 MA(20) :  6.47
MA(100) :  6.56 MA(250) :  6.95
MACD MACD :  -0.3 Signal :  -0.1
%K %D K(14,3) :  4.8 D(3) :  6
RSI RSI(14): 32.4
52-week High :  11 Low :  4.92
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NBTX ] has closed above bottom band by 7.9%. Bollinger Bands are 86.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.41 - 5.45 5.45 - 5.48
Low: 5.25 - 5.29 5.29 - 5.32
Close: 5.3 - 5.36 5.36 - 5.41
Company Description

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Headline News

Thu, 13 Jun 2024
(NBTX) Trading Advice - Stock Traders Daily

Wed, 12 Jun 2024
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy ... - Clinton Herald

Tue, 11 Jun 2024
Voting Rights and Shares Capital of the Company - Walla Walla Union-Bulletin

Sat, 01 Jun 2024
Where are the Opportunities in (NBTX) - Stock Traders Daily

Tue, 28 May 2024
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual ... - Yahoo Finance UK

Fri, 24 May 2024
Nanobiotix S.A. (NASDAQ:NBTX) Forecasted to Earn FY2025 Earnings of $0.88 Per Share - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 47 (M)
Shares Float 23 (M)
Held by Insiders 0 (%)
Held by Institutions 19.7 (%)
Shares Short 55 (K)
Shares Short P.Month 53 (K)
Stock Financials
EPS -1.17
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.04
Profit Margin -109.7 %
Operating Margin 3.4 %
Return on Assets (ttm) -19.8 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 854.9 %
Gross Profit (p.s.) 0
Sales Per Share 0.76
EBITDA (p.s.) -0.51
Qtrly Earnings Growth 0 %
Operating Cash Flow -12 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -4.58
PEG Ratio 0
Price to Book value -133.75
Price to Sales 6.96
Price to Cash Flow -20.2
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android